Cycloheximide
别名: NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80
中文名称:放线菌酮,环己酰亚胺
目录号:S7418 Purity: 99%
此产品请避光密封保存。
Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80),一种抗真菌抗生素,是一种真核生物蛋白质合成(protein synthesis)抑制剂,对体内蛋白质合(protein synthesis)和 RNA 合成(RNA synthesis)的 IC50 分别为 532.5 nM 和 2880 nM。Cycloheximide抑制铁死亡并抑制自噬。Cycloheximide (NSC-185) 可用于诱导记忆障碍动物模型。在溶液中不稳定,请现配现用!此产品为危化品(急性毒性/易燃/皮肤腐蚀),请在穿戴防护面罩、防护手套和防护服后使用。 已取得危险化学品经营许可
CAS: 66-81-9
客户使用Selleck的Cycloheximide发表文献365篇
- Signal Transduct Target Ther, 2024 9(1):65
- Mol Cancer, 2024 23(1):143
- Mol Cancer, 2024 23(1):240
- Cell Metab, 2024 S1550-4131(24)00415-7
- Cell Metab, 2024 36(7):1598-1618.e11
- J Hematol Oncol, 2024 17(1):77
- J Hematol Oncol, 2024 17(1):78
- Signal Transduct Target Ther, 2023 8(1):66
- Cell Discov, 2023 9(1):92
- Mil Med Res, 2023 10(1):68
- Cell Metab, 2022 34(7):1023-1041.e8
- J Hematol Oncol, 2022 15(1):122
- Nat Metab, 2022 4(9):1202-1213
- Signal Transduct Target Ther, 2020
- Bioact Mater, 2024 32:277-291
- Nat Commun, 2024 15(1):5209
- Nat Commun, 2024 15(1):3445
- Nat Commun, 2024 15(1):10303
- Nat Commun, 2024 15(1):1282
- Cancer Commun (Lond), 2024 10.1002/cac2.12595
- J Clin Invest, 2024 135(1)e179874
- Adv Sci (Weinh), 2024 11(39):e2400107
- Adv Sci (Weinh), 2024 11(32):e2400952
- Adv Sci (Weinh), 2024 11(35):e2308417
- Cell Rep Med, 2024 S2666-3791(24)00179-4
- Cell Rep Med, 2024 5(3):101477
- Autophagy, 2024 1-18.
- Exp Mol Med, 2024 56(1):177-191
- Gut Microbes, 2024 16(1):2382766
- Redox Biol, 2024 72:103137
- Redox Biol, 2024 73:103182
- Redox Biol, 2024 75:103292
- Redox Biol, 2024 69:103008
- J Exp Clin Cancer Res, 2024 43(1):248
- J Adv Res, 2024 S2090-1232(24)00079-1
- J Adv Res, 2024 S2090-1232(24)00496-X
- Clin Transl Med, 2024 14(10):e70039
- Clin Transl Med, 2024 14(5):e1686
- Int J Biol Sci, 2024 20(1):182-199
- Int J Biol Sci, 2024 20(13):5254-5271
- Int J Biol Sci, 2024 20(13):5223-5238
- Int J Biol Sci, 2024 20(6):2323-2338
- Int J Biol Sci, 2024 20(4):1125-1141
- Cell Death Dis, 2024 15(8):587
- Cell Death Dis, 2024 15(9):655
- Cell Death Dis, 2024 15(5):319
- Cell Death Dis, 2024 15(9):642
- Cell Death Dis, 2024 15(2):175
- Cell Death Dis, 2024 15(7):516
- Cell Death Dis, 2024 15(11):793
- Cell Death Dis, 2024 15(2):153
- Cell Rep, 2024 43(8):114608
- Cell Rep, 2024 43(10):114812
- Cell Rep, 2024 43(9):114727
- Cell Commun Signal, 2024 22(1):117
- Cell Commun Signal, 2024 22(1):516
- Cell Mol Biol Lett, 2024 29(1):103
- Cell Mol Biol Lett, 2024 29(1):146
- Cell Mol Life Sci, 2024 81(1):101
- Oncogene, 2024 43(6):406-419
- EMBO Rep, 2024 25(10):4337-4357
- EMBO Rep, 2024 25(12):5599-5619
- Elife, 2024 13RP94605
- J Transl Med, 2024 22(1):193
- J Transl Med, 2024 22(1):272
- J Med Chem, 2024 67(21):19216-19233
- Apoptosis, 2024 10.1007/s10495-024-02042-4
- Cell Death Discov, 2024 10(1):334
- Cell Death Discov, 2024 10(1):150
- Cell Death Discov, 2024 10(1):419
- Cell Death Discov, 2024 10(1):177
- Cell Death Discov, 2024 10(1):454
- Ecotoxicol Environ Saf, 2024 279:116446
- PLoS Pathog, 2024 20(4):e1012141
- Mol Oncol, 2024 10.1002/1878-0261.13637
- Oncogenesis, 2024 13(1):27
- Chin Med J (Engl), 2024 10.1097/CM9.0000000000002946
- Commun Biol, 2024 7(1):1365
- J Genet Genomics, 2024 S1673-8527(24)00360-6
- NPJ Breast Cancer, 2024 10(1):38
- Cancer Cell Int, 2024 24(1):207
- Cancer Cell Int, 2024 24(1):322
- iScience, 2024 27(7):110225
- Biochem Pharmacol, 2024 223:116198
- Expert Opin Ther Targets, 2024 1-13.
- iScience, 2024 27(8):110598
- Cancer Cell Int, 2024 24(1):38
- Int J Mol Sci, 2024 25(15)8383
- Biol Direct, 2024 19(1):82
- Biol Direct, 2024 19(1):13
- J Virol, 2024 98(2):e0188823
- BMC Plant Biol, 2024 24(1):1148
- Am J Cancer Res, 2024 14(5):2584-2607
- Am J Cancer Res, 2024 14(8):3773-3788
- Hepatol Commun, 2024 8(3)e0396
- Transl Oncol, 2024 51:102164
- Transl Oncol, 2024 46:101999
- J Biol Chem, 2024 300(4):107146
- J Biol Chem, 2024 300(3):105671
- J Biol Chem, 2024 301(1):108070
- J Biol Chem, 2024 300(11):107823
- Sci Rep, 2024 14(1):29579
- Sci Rep, 2024 14(1):6655
- Sci Rep, 2024 14(1):12090
- Toxicology, 2024 509:153980
- Vet Res, 2024 55(1):63
- Heliyon, 2024 10(11):e32571
- J Cancer, 2024 15(18):5876-5896
- J Cancer, 2024 15(5):1366-1377
- J Cancer, 2024 15(10):3173-3182
- Acta Biochim Biophys Sin (Shanghai), 2024 56(7):1044-1054
- Oncol Lett, 2024 28(3):406
- Oncol Lett, 2024 27(3):105
- Open Life Sci, 2024 19(1):20220935
- Clin Respir J, 2024 18(8):e13824
- bioRxiv, 2024 2024.02.02.578698
- FASEB Bioadv, 2024 6(11):555-564
- J Ginseng Res, 2024 48(1):40-51
- Nat Prod Bioprospect, 2024 14(1):18
- Res Sq, 2024 rs.3.rs-4899860
- Nat Commun, 2023 14(1):224
- Nat Commun, 2023 14(1):4758
- Nat Commun, 2023 10.1038/s41467-023-43439-0
- Nat Commun, 2023 14(1):5242
- Nat Commun, 2023 14(1):6635
- Cancer Commun (Lond), 2023 10.1002/cac2.12460
- Mol Cell, 2023 S1097-2765(22)01216-3
- J Clin Invest, 2023 133(3)e158705
- Adv Sci (Weinh), 2023 10(25):e2301753
- Adv Sci (Weinh), 2023 10(27):e2302025
- Adv Sci (Weinh), 2023 10(14):e2204438
- Adv Sci (Weinh), 2023 10(26):e2302002
- Adv Sci (Weinh), 2023 10(25):e2301088
- Cell Rep Med, 2023 4(4):101015
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101286
- Cell Death Differ, 2023 30(8):1988-2004
- J Exp Clin Cancer Res, 2023 42(1):146
- J Exp Clin Cancer Res, 2023 42(1):195
- J Exp Clin Cancer Res, 2023 42(1):33
- EMBO Mol Med, 2023 10.15252/emmm.202217367
- Research (Wash D C), 2023 6:0276
- Clin Transl Med, 2023 13(1):e1158
- J Nanobiotechnology, 2023 21(1):117
- MedComm (2020), 2023 4(5):e352
- Pharmacol Res, 2023 197:106955
- Int J Biol Sci, 2023 19(3):950-966
- Int J Biol Sci, 2023 19(2):377-392
- Cell Death Dis, 2023 14(9):588
- Cell Death Dis, 2023 14(2):153
- Cell Death Dis, 2023 14(2):102
- Cell Death Dis, 2023 14(7):402
- Cell Death Dis, 2023 14(7):482
- Cell Death Dis, 2023 14(2):159
- Cell Death Dis, 2023 14(1):2
- Cell Death Dis, 2023 14(4):259
- Mol Ther Nucleic Acids, 2023 32:343-358
- Cell Rep, 2023 42(10):113211
- Eur J Cancer, 2023 188:49-63
- Cell Commun Signal, 2023 21(1):356
- Oncogene, 2023 42(22):1843-1856
- Oncogene, 2023 10.1038/s41388-023-02856-7
- Oncogene, 2023 10.1038/s41388-023-02809-0
- J Cell Biol, 2023 222(1)e202205045
- Elife, 2023 12e91453
- Br J Pharmacol, 2023 10.1111/bph.16058
- Cell Death Discov, 2023 9(1):48
- Cell Death Discov, 2023 9(1):316
- Cell Death Discov, 2023 9(1):351
- Cell Death Discov, 2023 9(1):387
- PLoS Pathog, 2023 19(4):e1011314
- Cell Oncol (Dordr), 2023 10.1007/s13402-023-00779-9
- J Lipid Res, 2023 64(3):100342
- Commun Biol, 2023 6(1):1252
- Nutrients, 2023 15(12)2774
- Commun Biol, 2023 6(1):805
- Commun Biol, 2023 6(1):211
- Cancer Cell Int, 2023 23(1):304
- iScience, 2023 26(7):107003
- iScience, 2023 26(7):107151
- Cancer Cell Int, 2023 23(1):5
- iScience, 2023 26(1):105745
- iScience, 2023 26(6):106914
- Cancer Cell Int, 2023 23(1):220
- J Transl Med, 2023 21(1):670
- Int J Mol Sci, 2023 24(11)9157
- Int Immunopharmacol, 2023 123:110761
- Int J Mol Sci, 2023 24(10)8794
- J Virol, 2023 e0198422.
- Am J Cancer Res, 2023 13(2):452-463
- Am J Cancer Res, 2023
- Transl Oncol, 2023 35:101732
- Cell Signal, 2023 110:110851
- J Integr Med, 2023 21(6):584-592
- J Biol Chem, 2023 299(6):104825
- J Biol Chem, 2023 10.1016/j.jbc.2023.105395
- Molecules, 2023 28(7)2939
- Mol Carcinog, 2023 62(5):700-715
- Poult Sci, 2023 102(11):103026
- Gut Pathog, 2023 15(1):6
- BMC Complement Med Ther, 2023 23(1):111
- Dis Markers, 2023 2023:5899662
- Arch Physiol Biochem, 2023 1-9.
- Neoplasma, 2023 10.4149/neo_2023_230323N162
- Sci Adv, 2023 9(25):eadg2339
- bioRxiv, 2023 10.1101/2023.03.20.533404
- Sci Transl Med, 2022 14(638):eabc7480
- Nat Commun, 2022 13(1):1444
- Nat Commun, 2022 13(1):894
- Nat Commun, 2022 13(1):3419
- Nat Commun, 2022 13(1):7799
- Cancer Commun (Lond), 2022 10.1002/cac2.12311
- Adv Sci (Weinh), 2022 9(25):e2201701
- Acta Pharm Sin B, 2022 12(9):3602-3617
- Autophagy, 2022 42370
- Exp Mol Med, 2022 54(11):2047-2059
- Cell Death Differ, 2022 10.1038/s41418-022-00984-3
- Theranostics, 2022 12(4):1500-1517
- Redox Biol, 2022 59:102564
- Redox Biol, 2022 52:102292
- Redox Biol, 2022 50:102260
- EMBO J, 2022 e110439
- J Exp Clin Cancer Res, 2022 41(1):239
- Proc Natl Acad Sci U S A, 2022 119(36):e2117396119
- Proc Natl Acad Sci U S A, 2022 119(3)e2114134119
- J Immunother Cancer, 2022 10(3)e004026
- Clin Transl Med, 2022 12(1):e686
- Clin Transl Med, 2022 12(9):e1042
- Haematologica, 2022 10.3324/haematol.2022.281167
- Cancer Lett, 2022 549:215921
- Int J Biol Sci, 2022 18(6):2439-2451
- Int J Biol Sci, 2022 18(10):4171-4186
- Int J Biol Sci, 2022 18(8):3107-3121
- Int J Biol Sci, 2022 18(5):2132-2145
- Cell Death Dis, 2022 13(8):751
- Cell Death Dis, 2022 13(12):1053
- Cell Death Dis, 2022 13(5):497
- Cell Death Dis, 2022 13(2):150
- Cell Death Dis, 2022 13(3):249
- Cell Death Dis, 2022 13(7):643
- Cell Rep, 2022 40(3):111127
- Cell Rep, 2022 38(13):110559
- Cell Rep, 2022 40(7):111194
- Cell Rep, 2022 38(11):110513
- Cell Rep, 2022 41(12):111850
- Cell Rep, 2022 40(1):111035
- Cell Prolif, 2022 55(9):e13273
- Acta Pharmacol Sin, 2022 10.1038/s41401-022-00905-7
- Oncogene, 2022 10.1038/s41388-022-02352-4
- Oncogene, 2022 10.1038/s41388-022-02197-x
- EMBO Rep, 2022 e53373
- Cell Biosci, 2022 12(1):167
- Stem Cell Res Ther, 2022 13(1):398
- Front Immunol, 2022 13:853194
- Cell Mol Gastroenterol Hepatol, 2022 S2352-345X(22)00216-8
- Cell Death Discov, 2022 8(1):361
- Cell Death Discov, 2022 8(1):265
- J Invest Dermatol, 2022 S0022-202X(22)00081-1
- Oncogenesis, 2022 11(1):31
- Cells, 2022 11(24)4031
- Commun Biol, 2022 5(1):887
- Commun Biol, 2022 5(1):1391
- Biochem Pharmacol, 2022 207:115355
- Front Cell Infect Microbiol, 2022 12:759077
- Front Pharmacol, 2022 13:925489
- Front Pharmacol, 2022 13:1027441
- Front Cell Dev Biol, 2022 10:961675
- Biol Direct, 2022 17(1):41
- J Virol, 2022 96(14):e0212721
- Am J Cancer Res, 2022 12(8):3729-3744
- Am J Cancer Res, 2022 12(3):1069-1087
- J Cell Mol Med, 2022 10.1111/jcmm.17210
- J Cell Mol Med, 2022 26(23):5755-5766
- Mol Cancer Res, 2022 MCR-22-0415
- Aging (Albany NY), 2022 14(24):10050-10066
- Chem Biol Interact, 2022 364:110060
- Bioengineered, 2022 13(4):9106-9116
- J Biol Chem, 2022 298(7):102106
- J Biol Chem, 2022 S0021-9258(22)01208-X
- J Biol Chem, 2022 S0021-9258(22)00362-3
- Front Oncol, 2022 12:785345
- Stem Cells Int, 2022 2022:3705637
- Biology (Basel), 2022 11(10)1397
- Cancer Med, 2022 10.1002/cam4.5322
- Biomed Res Int, 2022 2022:9235837
- Cancer Biol Ther, 2022 23(1):265-280
- Cancer Biol Ther, 2022 1-10
- Exp Eye Res, 2022 220:109110
- Med Oncol, 2022 39(4):48
- Biochem Biophys Res Commun, 2022 623:140-147
- Biochem Biophys Res Commun, 2022 593:122-128
- Biochem Biophys Res Commun, 2022 606:68-74
- Open Med (Wars), 2022 17(1):1-14
- Biomaterials, 2021 271:120720
- Autophagy, 2021 10.1080/15548627.2021.1912270
- Autophagy, 2021 10.1080/15548627.2021.2008692
- Theranostics, 2021 11(2):700-714
- Theranostics, 2021 11(6):2655-2669
- J Exp Clin Cancer Res, 2021 40(1):279
- J Exp Clin Cancer Res, 2021 40(1):201
- MedComm (2020), 2021 2(4):821-837
- Cancer Lett, 2021 504:104-115
- Pharmacol Res, 2021 174:105927
- Cell Death Dis, 2021 12(3):239
- Cell Death Dis, 2021 13(1):10
- Mol Ther Nucleic Acids, 2021 25:554-566
- Cell Rep, 2021 34(10):108814
- Mol Ther Nucleic Acids, 2021 26:798-812
- Cell Rep, 2021 35(7):109159
- Oncogene, 2021 10.1038/s41388-021-01890-7
- Oncogene, 2021 40(25):4291-4306
- Phytomedicine, 2021 95:153861
- EMBO Rep, 2021 e51436
- Front Immunol, 2021 12:802795
- Eur J Med Chem, 2021 217:113376
- Commun Biol, 2021 4(1):1391
- Biochem Pharmacol, 2021 188:114562
- Cancer Sci, 2021 112(11):4593-4603
- Int J Mol Sci, 2021 22(10)5306
- Int Immunopharmacol, 2021 95:107552
- Front Cell Dev Biol, 2021 9:635424
- Front Cell Dev Biol, 2021 9:779718
- Front Cell Dev Biol, 2021 9:670145
- Cancer Biol Med, 2021 18(1):227-244
- J Virol, 2021 JVI0059421
- Cancers (Basel), 2021 13(17)4425
- Cancers (Basel), 2021 13(5)1181
- ACS Chem Neurosci, 2021 10.1021/acschemneuro.1c00131
- Transl Oncol, 2021 14(9):101148
- J Biol Chem, 2021 297(5):101275
- FASEB J, 2021 35(3):e21351
- Front Oncol, 2021 11:668798
- Biology (Basel), 2021 10(3)234
- Cell Biol Int, 2021 10.1002/cbin.11744
- Exp Cell Res, 2021 S0014-4827(21)00262-7
- Dis Markers, 2021 2021:3771990
- Front Neurol, 2021 12:652882
- Oncol Lett, 2021 21(5):394
- Anticancer Drugs, 2021 32(6):664-673
- ACS Nano, 2020 10.1021/acsnano.0c08947
- J Exp Clin Cancer Res, 2020 39(1):170
- J Exp Clin Cancer Res, 2020 39(1):172
- Cell Death Dis, 2020 11(8):615
- Biomed Pharmacother, 2020 133:110965
- Commun Biol, 2020 3(1):732
- Front Pharmacol, 2020 11:550469
- J Cell Physiol, 2020 10.1002/jcp.30172
- Virol Sin, 2020 10.1007/s12250-020-00320-4
- J Cell Mol Med, 2020 10.1111/jcmm.15831
- Am J Cancer Res, 2020 10(6):1691-1709
- FASEB J, 2020 10.1096/fj.202000268RRR
- Environ Toxicol, 2020 10.1002/tox.23032
- Oncol Rep, 2020 44(4):1365-1374
- Cancer Med, 2020 10.1002/cam4.3492
- Oncogene, 2019 38(46):7133-7145
- J Virol, 2019 93(4)e01896-18
- Cell Physiol Biochem, 2019 53(6):999-1014
- Exp Cell Res, 2019 15;382(2):111466
- Integr Cancer Ther, 2019 18:1534735418822120
- Cell Rep, 2018
- Chem Res Toxicol, 2018 31(2):127-136
- Oncotarget, 2017 8(39):65946-65956
- Oncotarget, 2017 8(19):31297-31304
- Journal of Functional Foods, 2017 31:217-228
- Oncogene, 2016 35(28):3681-91
- Cell Cycle, 2016 15(21):2980-2991
化学信息&溶解度
分子量 | 281.35 |
分子式 | C15H23NO4 |
CAS号 | 66-81-9 |
Smiles | CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C |
储存条件(自收到货起) | 3年 -20°C(避光) 粉状 |
此产品性质不稳定,需现配现用!建议您购买分装规格,或者在收到货后进行分装。 |
体外溶解度 | 批次: |
DMSO : 56 mg/mL ( 199.04 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 56 mg/mL Water : 15 mg/mL DMSO : 56 mg/mL ( 199.04 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 56 mg/mL Water : 15 mg/mL |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 |
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。